Pioneering
Next-Generation Therapeutics
At MLS Bio, we are addressing the world's most critical health challenges through AI drug development platforms and innovative small-molecule therapies with our breakthrough compounds. We are targeting a new cellular mode of action, offering novel approaches to treatment in the most impactful global markets.
.avif)
Strategic Focus in Oncology
We are advancing therapeutics for solid Cancers with
Prostate Cancer as our lead indication
Lead Asset
MLS 269, first in class small molecule CD151 inhibitor targeting cancer metastasis
.svg)
Market Opportunity
USD$15.9B addressable prostate cancer therapeutics market
Stage
Proceeding to toxicology, Pre-IND FDA submission
Partnerships
The Prostate Cancer Clinical Trails Consortium
.png)
.svg)
Our
Commitment
Our Global team of experienced medical researchers, commercialization, and technical experts are committed to developing treatments that are more effective, accessible, and better tolerated, delivering novel solutions and improving the lives of patients facing cancer and other life-threatening diseases worldwide.
With our robust pipeline, we aim to develop solutions in other high-impact global markets, bringing transformative therapies to market and delivering better outcomes for patients facing cancer and other life-threatening diseases.
.avif)
.svg)
The Science
CD151, a tetraspanin family protein, is overexpressed in aggressive prostate cancer (PCa), promoting cell migration and invasion, hallmarks of metastasis.
It forms complexes with integrins (e.g., α3β1, α6β1), facilitating tumor cell motility, survival, and vascular invasion.
Experimental inhibition of CD151 results in a significant reduction in cancer cell migration and invasion in vitro and in vivo.
MLS-269 selectively targets the CD151-integrin interface, disrupting critical signaling required for metastatic dissemination.
This host - directed therapeutic approach reduces tumor invasiveness without directly targeting tumor proliferation - highlighting the possibility of limiting drug resistance.
Tetraspanins, particularly CD151, regulate cell motility and promote tumour progression via integrin interactions. Despite their central role in cancer invasion and metastasis, they remain under-explored as therapeutic targets.
Addresses a key driver of cancer progression: metastatic spread.
First-in-class mechanism offers potential for: Survival extension in mCRPC and nmCRPC populations.
Pre-Clinical Validation: MLS 269 reduces prostate cancer tumors, sustained effect over time with body weight neutral or positive profile.
Indication expansion into other CD151-high malignancies (e.g., kidney, lung, pancreatic, breast).
Results suggest that CD151 could be a potential biomarker for prognosis and as a diagnostic in prostate cancer, where higher CD151 levels correlate with reduced survival.
First-in-class therapy innovation targeting cancer metastasis - the leading cause of cancer death - with the potential to significantly extend survival in treatment-resistant prostate and other major solid cancers.
Comprehensive preclinical package supports the application of Phase 1b-2 trials in prostate cancer. A robust translational foundation that de-risks progression to human studies.
Data (in-vivo) supports favourable tolerability when compared to standard of care treatments.
MLS-269 delivers a differentiated anti-metastatic profile in a market dominated by androgen signaling therapies - positioning it for premium pricing, partnership optionality, and potential platform expansion across solid tumors.
Addressing Challenges in
Advanced Cancer Care
Existing therapies provide only partial solutions, with limitations in tolerability and efficacy against resistant, late-stage disease
Limited Options for Advanced Cancer:
Existing therapies offer only modest benefit for advanced or metastatic disease.
High Treatment Costs:
Access to life-saving treatments remains cost-prohibitive for many patients.
Poor Tolerability:
Severe side effects reduce quality of life and limit treatment adherence.
MLS Bio is transforming patient outcomes by redefining the standard of care in prostate cancer — delivering new hope to patients with advanced disease by expanding treatment options, improving access, and ensuring quality of life through safer, more tolerable therapies
Clinical Significance
Addresses a key driver of prostate cancer progression: metastatic spread.
First-in-class mechanism offers potential for:
Survival extension in mCRPC and nmCRPC populations
Indication expansion into other CD151-high malignancies (e.g., kidney, lung, pancreatic, breast)
First-in-class therapy innovation targeting cancer metastasis - the leading cause of cancer death - with the potential to significantly extend survival in prostate and other major solid cancers.
Preclinical
Validation
Strong In Vivo Efficacy Demonstrated
Our preclinical studies show compelling results:
CD151 as a viable
therapeutic target
Data supports that CD151 is a functional driver of prostate cancer cell migration and invasion. Its overexpression in LNCaP cells, which normally express low endogenous CD151, significantly enhances aggressive phenotypes, highlighting CD151 as a viable therapeutic target in metastatic prostate cancer.
.png)
CD151 significantly suppresses both cell migration and invasion
CD151 is a critical regulator of metastatic potential in prostate cancer cells. Its silencing via siRNA significantly suppresses both cell migration and invasion, providing strong in vitro evidence that CD151 is a functional driver of prostate cancer aggressiveness and a promising therapeutic target.
MLS 269 Reduces
Prostate Cancer
MLS Anti-CD151 therapies demonstrate marked tumour suppression, outperforming existing leading therapies. Strong In vivo efficacy demonstrated, MLS 269 reduces prostate cancer tumours, with sustained effect over time.
.png)
Tolerability improved to standard of care
MLS Bio Anti-CD151 therapies demonstrated a body weight–neutral or positive profile, supporting favourable tolerability when compared to standard-of-care treatments.
%20(1).png)
Diagnostic Potential
Results illustrate CD151 correlation that suggests that it could be a potential biomarker for prognosis and as a diagnostic in prostate cancer, where higher CD151 levels correlate with reduced survival.
Conclusion:
MLS Anti-CD151 therapies demonstrate marked tumour suppression, outperforming existing leading therapies and validating CD151 as a promising therapeutic target in metastatic prostate cancer.
.png)
Pipeline
Our Development Portfolio
Leading with Oncology, Expanding Across High-Impact Markets
- Target: First-in-class CD151 tetraspanin inhibitor
- Indication: Metastatic castration-resistant prostate cancer (mCRPC)
- Stage: Proceeding to toxicology, Pre IND-FDA submission & Phase 1b/2 clinical trials.
- Market Opportunity: $15.9B global prostate cancer therapeutics market
- Regulatory Status: Pre IND FDA submission: fast track; breakthrough therapy; priority review
- Target: First in class viral entry inhibitor; in vivo reversing lung damage from infection.
- Indication: Human Health - Broad-spectrum anti-viral, viruses: CMV and Corona Viruses
- Stage: Proceeding to toxicology & Phase 1b/2 Clinical trials.
- Market Opportunity: $85B+ antiviral market by 2030
- Regulatory Status: MLS 289 has PRE–IND FDA approval
- Target: First in class anti-viral agent inhibiting the function of CD181
- Indication: Porcine Reproductive Respiratory Syndrome (PRRS) – all strains
- Impact: Addresses >$2.5B in annual swine industry losses
- Stage: Phase 1/2 large herd trials
- Pathway: Accelerated regulatory pathways (APVMA, FDA-CVM)
- Path to Market with Progressive Market Registrations and combination therapies.
- Clear Platform Expansion Potential
- MLS 269 Expected to be effective in multiple solid tumour cancers
- Oncology Pipeline Comprehensive Expansion:
A successful regulatory and clinical blueprint in prostate cancer de-risks expansion, into other solid tumours, enabling label extensions or new analogues across a high-value platform technology model.
.avif)
Clinical Development
Development Timeline: Clear Path to Clinical Proof-of-Concept, Registration and Exit
Clinical Research Strategy
Toxicology Studies
MLS Bio’s Anti-CD151 therapies have shown strong tolerability in preclinical models, with animals maintaining or gaining weight. This supports high confidence in positive toxicology results, which are expected within 8–10 months and represent a key value-inflection milestone for the company.
Phase 1b/2 Clinical Trials
Evaluate safety, pharmacokinetics & preliminary anti-tumour efficacy in patients with advanced prostate cancer, establishing human data and a recommended dose for Phase 3 trials.
Clinical Partnership
Excellence
Prostate Cancer Clinical Trials Consortium (PCCTC)
Global clinical leadership
Memorial Sloan Kettering Cancer Center
Leading clinical trial partnership
AusBiotech and BioMelbourne Network
National and state industry association support
Regulatory Advantages
Accelerating Access, Maximizing Value
FDA Breakthrough Therapy Designation and Priority Review
Accelerating time-to-market
Global Regulatory Harmonization
ICH-aligned strategy for parallel submissions
Global Regulatory Affairs Strategy
Lead by Pace Analytical, USA. With deep experience across life sciences sectors, supports a clear route from discovery to clinic.
Our Team
The leadership and advisory at MLS Bio brings together internationally distinguished commercial and scientific expertise encompassing key capabilities for successful pharmaceutical commercialisation. The Board and executive leaders include key experts in financial and legal governance, intellectual property and global regulatory strategy together with commercially experienced professionals who have successfully scaled medical ventures to global exits, directed multi-billion-dollar investment funds, and advanced transformative therapies into international markets. Strengthened by a world-class Scientific Advisory Board—comprising pre-eminent oncologists, endocrinologists, infectious disease specialists, and translational medicine authorities. This combination of scientific rigor, commercial acumen, and governance discipline ensures that MLS Bio is uniquely positioned to advance a portfolio of breakthrough small-molecule therapeutics, driving innovation to patient impact, while delivering sustainable value to investors.
James LaFlamme, RPh, MS, FACHE — Healthcare executive with 30+ years’ global experience; founder of BioPharma Global and former senior leader at Coté Orphan, NCQA, and PwC.
James LaFlamme is a senior healthcare executive with more than 30 years of experience across clinical, regulatory, and commercial domains. He is the founder and former Chief Executive Officer of BioPharma Global, where he led international operations and advisory services supporting drug developers focused on rare and underserved conditions. Under his leadership, the company was successfully acquired by Pace Analytical Life Sciences.
Previously, James served as Executive Vice President at Coté Orphan, directing global regulatory and business development strategy; held a senior role at the National Committee for Quality Assurance (NCQA) overseeing accreditation and recognition programs; and led healthcare advisory and transformation initiatives within PwC’s Public Sector Healthcare Advisory practice.
James holds a Bachelor of Science in Pharmacy from the University of Connecticut and a Master’s in Management from Indiana Wesleyan University. He is a Fellow of the American College of Healthcare Executives and serves on the Dean’s Advisory Board at the UConn School of Pharmacy.
Professor Albert Frauman MD, FRACP, FACP — Physician-scientist and biotech founder; clinical pharmacology leader at University of Melbourne and Austin Health, with 40 years’ translational research expertise.
Professor Albert Frauman is a physician-scientist and translational biotech entrepreneur with four decades of clinical and academic leadership. He is Chair in Clinical Pharmacology and Therapeutics at the University of Melbourne and Director of Clinical Pharmacology at Austin Health. A board-certified endocrinologist and fellow of multiple international medical colleges, he has authored more than 70 peer-reviewed papers on autoimmunity, viral infection, oncology, and pharmacovigilance. His research and translational expertise underpin MLS Bio’s programs in oncology and infectious disease.
Penelope Lane B.Bus/B.Sc., MS, MPH (Int. Health Eco.), AICD — CEO & Managing Director of MLS Bio, global biotech leader with 20+ years’ experience translating science into health impact, scaling ventures, and securing international investment across five continents.
Penelope Lane is a global biotech and healthcare executive with over 20 years of leadership across five continents. As CEO and Managing Director of MLS Bio, she has assembled a world-class team advancing small-molecule therapeutics in oncology and infectious disease. Penelope previously scaled an Australian medical simulation venture through to a successful exit to Terumo Corporation and earlier led the WHO- and Gates Foundation-backed BlueStar health franchise across ten countries. She also founded Vert & Or Ventures, serves on global advisory boards (including Sheba Medical Center and RMIT), and is an active biotech investor.
Grant Dooley BA (Asian Studies) MIA — Global financial and investment leader and former CEO of Breakthrough Victoria, with deep expertise in global venture capital, funds management, capital formation and investment across Australia and Asia.
Grant Dooley is a seasoned investment and fund-management executive with more than 20 years of experience leading large-scale capital deployment across infrastructure, venture capital, and sovereign funds. As the inaugural CEO of Breakthrough Victoria, he established and led a $2 billion innovation and commercialisation fund that deployed over $350 million across 27 companies and six university platforms. He previously served as CEO of ARA Infrastructure (Singapore), Executive Director at Hastings Funds Management, and Australian Consul-General in Guangzhou with DFAT. Grant brings deep expertise in global investment strategy, venture and private capital, and cross-border partnership governance.
Dr Jenny Petering Ph.D., ITPA — NED, leading patent attorney and biotech IP strategist; Of Counsel at FB Rice, Senior Fellow at Melbourne Law Masters, and advisor to early-stage biotech innovators through AusBiotech, IPSANZ, IMNIS and Scale Angels.
Dr Jenny Petering is an Australian and New Zealand-registered patent attorney with extensive experience in biotechnology intellectual property. As Of Counsel with FB Rice, she manages complex international patent portfolios and advises on strategic IP planning, due diligence, and opposition proceedings. She has been recognised as an MIP IP Star (2019–2022) and listed in IAM Strategy 300 Global Leaders (2021–2025). Jenny holds a PhD in Molecular Biology from the University of Adelaide and a BSc (Hons) in Biochemistry & Genetics from Monash University. She is a Senior Fellow in the Melbourne Law Masters Program and a mentor through AusBiotech, IMNIS, and Scale Angels.
Paul Scagliotti BCom/BLaw, MLaw, FGIA — Leading commercial lawyer and company secretary; governance and compliance specialist with expertise in commercialisation transactions, IP strategy, and research partnership and investment structuring.
Paul Scagliotti is an experienced commercial lawyer and company secretary with a strong record in corporate governance, regulatory compliance, and transaction advisory across biotech, higher education, and advanced manufacturing. He specialises in contract negotiation, intellectual property strategy, and investment structuring. A Fellow of the Governance Institute of Australia, Paul has served as General Counsel and CFO at Concepta Group and held senior legal roles at leading Australian universities. He is currently Director at Vert & Or Legal, providing strategic legal and governance advice to innovation-driven companies.
Adrian Hondros BCom, Grad Dip App Fin, Grad Dip Prof Acc — Finance and strategy executive with 38+ years’ leadership across banking, insurance, construction and biotech; Founder of Hondros Consulting.
Adrian Hondros is an experienced financial services and strategy executive with nearly four decades of leadership experience across banking, insurance, construction, and biotechnology. Over the past three years (2022 – 2025) he has served as a Non-Executive Director of MLS Bio, where he has overseen and contributed to a period of significant transformational change, strengthening the company’s investment relationships and positioning it for growth. Adrian’s broader career includes senior executive roles at NAB and CBA, as well as serving as CEO of St Andrew’s Australia and Porter Davis Homes. As Founder and Managing Director of Hondros Consulting, he continues to advise boards and CEOs on leadership, strategy, and governance to achieve sustainable growth and deliver long-term value. “We are delighted that Adrian will continue to contribute his expertise and leadership to MLS Bio in his new role as Board Observer, ensuring the company continues to benefit from his experience and insights during this next stage of growth.” Professor Albert Frauman, Founding Director.
Holly Stefl BSc — Commercial executive with 20+ years’ experience leading global growth strategies across pharmaceutical services and biotechnology in the US and Australia; expert in biotech services, clinical development and R&D funding strategies.
Holly Stefl is a commercial executive with over 20 years of experience leading global growth strategies across pharmaceutical and biotech sectors in the US and Australia. She served as Chief Commercial Officer at Endpoints Capital, providing non-dilutive R&D funding to biotech companies. Previously, she was CCO at Agilex Biolabs, driving its growth and sale to Healius (ASX:HLS), and held senior roles at IQVIA, Quintiles, and an oncology biotech. Holly brings expertise in clinical operations, commercialisation strategy, and global drug development.
Penelope Lane — CEO & Managing Director of MLS Bio, global biotech leader with 20+ years’ experience translating science into health impact, scaling ventures, and securing international investment across five continents.
Penelope Lane is a global biotech and healthcare executive with over 20 years of leadership across five continents. As CEO and Managing Director of MLS Bio, she has assembled a world-class team advancing small-molecule therapeutics in oncology and infectious disease. Penelope previously scaled an Australian medical simulation venture through to a successful exit to Terumo Corporation and earlier led the WHO- and Gates Foundation-backed BlueStar health franchise across ten countries. She also founded Vert & Or Ventures, serves on global advisory boards (including Sheba Medical Center and RMIT), and is an active biotech investor.
Professor Albert Frauman — Physician-scientist and biotech founder; clinical pharmacology leader at University of Melbourne and Austin Health, with 40 years’ translational research expertise.
Professor Albert Frauman is a physician-scientist and translational biotech entrepreneur with four decades of clinical and academic leadership. He is Chair in Clinical Pharmacology and Therapeutics at the University of Melbourne and Director of Clinical Pharmacology at Austin Health. A board-certified endocrinologist and fellow of multiple international medical colleges, he has authored more than 70 peer-reviewed papers on autoimmunity, viral infection, oncology, and pharmacovigilance. His research and translational expertise underpin MLS Bio’s programs in oncology and infectious disease.
Thomas Collins — Chartered Accountant and CFO with expertise in corporate finance, investment management and strategic financial leadership; experienced investor in listed and early-stage innovative companies.
Thomas Collins is a Chartered Accountant with extensive experience in corporate finance, investment management, and financial operations. He has led financial reporting for both listed and private entities, managed capital structuring and compliance, and aligned finance systems with strategic goals. As CFO and Financial Controller of MLS Bio, Thomas oversees reporting, governance, and financial strategy to enable sustainable growth. Known for analytical discipline and strategic foresight, he brings rigour and stability to executive leadership.
Paul Scagliotti — Leading commercial lawyer and company secretary; governance and compliance specialist with expertise in commercialisation transactions, IP strategy, and research partnership and investment structuring.
Paul Scagliotti is an experienced commercial lawyer and company secretary with a strong record in corporate governance, regulatory compliance, and transaction advisory across biotech, higher education, and advanced manufacturing. He specialises in contract negotiation, intellectual property strategy, and investment structuring. A Fellow of the Governance Institute of Australia, Paul has served as General Counsel and CFO at Concepta Group and held senior legal roles at leading Australian universities. He is currently Director at Vert & Or Legal, providing strategic legal and governance advice to innovation-driven companies.
Former CSL President and CFO; biotech strategy advisor with deep expertise in global operations and vaccine commercialisation.
Gordon Naylor is a former President of CSL Seqirus and CFO of CSL Limited, with decades of experience in biotech finance and global operations. He provides strategic advice on biotech commercialisation, corporate governance, and international market expansion, drawing on his leadership in vaccine manufacturing and public health commercial strategy.
Pharmaceutical chemistry expert and patent attorney; advisor to biotech and pharma firms on IP protection and portfolio strategy.
Dr Brittany Howard is a partner and patent attorney at FB Rice, specialising in pharmaceutical chemistry and intellectual property strategy. She advises biotech and pharma clients on patent prosecution, freedom-to-operate analysis, and portfolio commercialisation. Her scientific background in medicinal chemistry supports her role as a trusted advisor bridging research and commercial translation.
Global investor and medical technology entrepreneur guiding early-stage biotech innovation and commercialisation strategy.
Dr Alexander Gosling is a global investor and medical technology entrepreneur with a career spanning engineering innovation, commercial R&D, and strategic advisory. He has founded and invested in multiple med-tech ventures and provides guidance on technology commercialisation and product development strategies for early-stage biotech companies.
R&D tax and innovation funding expert helping biotech and med-tech companies translate science into sustainable business growth.
U.S.-based CFO advisor and financial strategist guiding biotech firms through growth, fundraising, and North American expansion.
Geoff Grisham is a chartered corporate finance professional and senior financial advisor specialising in U.S. market operations. He provides CFO-level advisory to biotechnology and healthcare organisations, guiding financial modelling, fundraising, and strategic expansion within North American markets.
Biotech executive and NED with extensive experience in R&D portfolio management and global clinical development.
Dr Jane Ryan is a biotechnology executive and clinical development leader with extensive experience managing R&D portfolios for listed biotech companies. She has served in senior scientific and non-executive director roles, advising on global clinical trials, regulatory pathways, and investor engagement strategies.
Global digital marketing leader specialising in biotech brand development, investor communications, and strategic positioning.
Kimberly Wells is the Global Practice Lead at TBWA Advertising and a senior digital marketing strategist with deep expertise in healthcare and biotech communications. She advises MLS Bio on global brand development, digital engagement, and investor relations strategies, leveraging her international experience in creative leadership and integrated marketing.
Pharmaceutical R&D expert advising on chemical drug development, formulation, and clinical-scale manufacturing.
Dr Ashley Bates is an experienced pharmaceutical R&D executive and consultant specialising in chemical drug development and manufacturing. He has held senior directorial roles in pharmaceutical research and advises MLS Bio on clinical formulation, scale-up, and regulatory compliance for small-molecule therapeutics.
Charles J. Ryan, MD
Genitourinary Medical Oncologist - Memorial Sloan Kettering Cancer Center. Host – The Good News About Cancer Podcast
World-leading Oncologist, Medical Director of The Prostate Cancer Clinical Trials Consortium, and former CEO of The Prostate Cancer Foundation.
Charles Ryan MD is a world leading genitourinary medical oncologist and internationally recognized prostate cancer researcher. With more than 25 years of experience, he has treated thousands of men with advanced and metastatic prostate cancer and led pioneering clinical trials that have shaped modern standards of care.
Formerly CEO of the Prostate Cancer Foundation, Dr. Ryan has also served as Chair of the NCI Prostate Cancer Task Force, and held the Thomas Perkins distinguished professorship at UCSF and the BJ Kennedy Chair at the University of Minnesota. He is the Medical Director of the Prostate Cancer Clinical Trials Consortium, previously held the position as Co-Chair of the National Cancer Institute’s Prostate Cancer Task Force, and led the design of clinical trials in advanced prostate cancer through the NCI's Alliance for Clinical Trials in Oncology. He has authored over 200 peer-reviewed publications, and wrote The Virility Paradox (2018), exploring the profound impact of testosterone on health and society.
At Memorial Sloan Kettering Cancer Center, Dr. Ryan delivers world-class care in prostate and genitourinary cancers, combining cutting-edge research, innovative therapies, and compassionate patient engagement.
Professor Albert Frauman — Physician-scientist and biotech founder; clinical pharmacology leader at University of Melbourne and Austin Health, with 40 years’ translational research expertise.
Professor Albert Frauman is a physician-scientist and translational biotech entrepreneur with four decades of clinical and academic leadership. He is Chair in Clinical Pharmacology and Therapeutics at the University of Melbourne and Director of Clinical Pharmacology at Austin Health. A board-certified endocrinologist and fellow of multiple international medical colleges, he has authored more than 70 peer-reviewed papers on autoimmunity, viral infection, oncology, and pharmacovigilance. His research and translational expertise underpin MLS Bio’s programs in oncology and infectious disease.
Director of the Department of Respiratory and Sleep Medicine at Austin Health. Professorial Fellow at the University of Melbourne and Adjunct Professor at Monash University, with additional affiliations at RMIT University and the Victorian Translational Research Institute (VicTRI).
Professor Christine McDonald AM FAHMS is an eminent physician-scientist specialising in respiratory and sleep medicine, with an illustrious career in clinical care, translational research, and academic leadership . She serves as the Director of the Department of Respiratory and Sleep Medicine at Austin Health and holds professorial appointments including Professorial Fellow at the University of Melbourne and Adjunct Professor at Monash University, with additional affiliations at RMIT University and the Victorian Translational Research Institute (VicTRI).
Her research centers on chronic lung diseases, pulmonary rehabilitation, oxygen therapy, and translational interventions from hospital to home settings, particularly in conditions like COPD and interstitial lung disease. She is the lead author of the current Thoracic Society of Australia and New Zealand (TSANZ) guidelines on domiciliary oxygen and has led NHMRC-supported clinical trials evaluating ambulatory oxygen in interstitial lung disease.
Recognized not just for her clinical and scientific impact but also for her commitment to education and mentorship, she was honoured in 2018 as a Member of the Order of Australia for her service to respiratory and sleep medicine as a clinician-researcher and administrator . Under her leadership, the Victorian Respiratory and Sleep team at Austin Health has received multiple prestigious awards for educational and research excellence.
Professor McDonald also contributes nationally through roles such as Editor in Chief of Respiratory Medicine Today, Chair of the COPD National Program for the Lung Foundation Australia, and membership on the COPD X Guidelines Committee.
Non-Executive Director Victorian Animal Aid Trust, former Dean College of Public Health, Medical and Veterinary Sciences – Jame Cook University, former Professor and Chair in Veterinary Clinical Sciences and Head of Melbourne Vet School University of Melbourne, consulting services to the veterinary pharmaceutical and veterinary clinical industries in Australia.
Professor Ted Whittem is a distinguished veterinary scientist and translational pharmacologist. Former Dean of the College of Public Health, Medical and Veterinary Sciences at James Cook University, he has authored over 20 studies on pharmacokinetics and pain management in animal health. He currently serves on the Animal Aid Board, contributing to governance and ethics in animal welfare. His expertise supports MLS Bio’s veterinary antiviral and pharmacology programs.
In Transition
Scientific Advisory Board Chair - Virology Stream
U.S.-based pharmaceutical executive with NASDAQ experience to join post–Series A to strengthen global clinical and regulatory expertise.
Partners
Building a network to accelerate our mission of MLS Bio has strategically developed a global ecosystem of world-class partners to accelerate the advancement of its pipeline. These strategic collaborations will strengthen the company’s scientific rigor, operational excellence, and international reach. This integrated network positions MLS Bio to accelerate the commercialisation of breakthrough science, bringing transformative therapies to patients and markets worldwide.
Academic
Med-Chem CMC
Drug Formulation
%201.avif)
Preclinical & Clinical
Government and
Industry Supporters
Clinical Excellence Partners
Prostate Cancer Clinical Trials Consortium (PCCTC) - Global clinical trial leadership
Memorial Sloan Kettering Cancer Center Leading cancer center partnership
Professional Services & Strategic Advisors
.svg)
FB Rice
Comprehensive IP strategy development
.svg)
Pace Analytical USA
Expert life-science regulatory partners advising on global regulatory strategy.
Intellectual
Property
Global Patent Portfolio
Strategic Value Creation
US & Australian Patents Granted
Maximise Patent Life: Regulatory Extensions
U.S. PTEs and European SPCs can extend exclusivity by up to 5 years
MLS-269's patents are active to 2041, an evergreen strategy to add 5–20 years, securing ROI
Strategic Filings and Prosecution: MLS Bio's integrated approach aligns patent prosecutionwith clinical milestones
MLS-269’s globally integrated patent extension strategy is a critical value driver extending revenue lifecycles, mitigating risks, enhancing investor returns, and strengthening positioning for strategic partnerships or acquisitions
Patent Strategy
View Patent StrategyInvestment
Thesis
MLS Bio offers investors a de-risked, high-upside opportunity with multiple exit pathways
Investor Insight: MLS Bio’s scientifically unified platform unlocks multi-channel revenue, strategic global partnerships, and high-value exit flexibility, positioning the company as a scalable, multi-sector growth engine that creates:
Multi-channel revenue streams
Cross-sector investment appeal
Optionality for future growth, partnerships, or divestitures
MLS 269 – Prostate Cancer
MLS Bio offers investors a de-risked, high-upside opportunity with multiple exit pathways offering near-term value inflection and long-term upside in a $15 B+ global prostate cancer market.
Differentiated Competitive & Clinical Advantage
Targeting a Significant and Growing Market
Substantial Commercial and Pricing Opportunity
Regulatory and IP Positioning for Longevity
Platform Expansion Potential
Multiple Market Validated Exit Opportunities; through M&A or Strategic Partnerships
News & Updates
“MLS Bio is pioneering small-molecule therapeutics that transform outcomes in prostate cancer, addressing the urgent need for effective options in advanced and resistant disease”
Contact Us
Leadership
Penelope Lane - Managing Director, Chief Executive Officer
penelope@mlsbio.com
Investor Relations
For investment opportunities and corporate updates:
investors@mlsbio.com
Business Development & Partnerships
For strategic partnerships and licensing opportunities:
partnerships@mlsbio.com
Corporate Information
MLS Bio
Level 10, 440 Collins Street Melbourne, Victoria 3000, Australia
Data Room Access
Comprehensive Data Room Available
Due Diligence scientific analysis, market information and financials available under CDA with suitable investor alignment.
Pioneering Next-Gen Therapies for Global Health